| Literature DB >> 35962721 |
Min Li1, Yide Wang1, Masaya Tachibana1, Shafiur Rahman2,3, Kuriko Kagitani-Shimono1.
Abstract
Patients with autism spectrum disorder (ASD) often show pervasive and complex language impairments that are closely associated with aberrant structural connectivity of language networks. However, the characteristics of white matter connectivity in ASD have remained inconclusive in previous diffusion tensor imaging (DTI) studies. The current meta-analysis aimed to comprehensively elucidate the abnormality in language-related white matter connectivity in individuals with ASD. We searched PubMed, Web of Science, Scopus, and Medline databases to identify relevant studies. The standardized mean difference was calculated to measure the pooled difference in DTI metrics in each tract between the ASD and typically developing (TD) groups. The moderating effects of age, sex, language ability, and symptom severity were investigated using subgroup and meta-regression analysis. Thirty-three DTI studies involving 831 individuals with ASD and 836 TD controls were included in the meta-analysis. ASD subjects showed significantly lower fractional anisotropy or higher mean diffusivity across language-associated tracts than TD controls. These abnormalities tended to be more prominent in the left language networks than in the right. In addition, children with ASD exhibit more pronounced and pervasive disturbances in white matter connectivity than adults. These results support the under-connectivity hypothesis and demonstrate the widespread abnormal microstructure of language-related tracts in patients with ASD. Otherwise, white matter abnormalities in the autistic brain could vary depending on the developmental stage and hemisphere. LAYEntities:
Keywords: autism spectrum disorder; diffusion tensor imaging; language networks; meta-analysis; white matter connectivity
Mesh:
Year: 2022 PMID: 35962721 PMCID: PMC9546367 DOI: 10.1002/aur.2789
Source DB: PubMed Journal: Autism Res ISSN: 1939-3806 Impact factor: 4.633
FIGURE 1PRISMA flow chart of the study selection
Study characteristics of included articles
| Study | Country | Number of subjects | Demographic characters of ASD | Diagnosis and assessment | |||||
|---|---|---|---|---|---|---|---|---|---|
| Study design | Sex ratio (% male) | Mean age ( | FSIQ/VIQ ( | Diagnosis type | Diagnostic criteria | IQ/VIQ assessment | |||
| Andica et al. ( | Japan | Cross‐sectional | 26 ASD 25 TD | 73.08 | 32.93 (9.24) | >80 | HFA | DSM‐IV; AQ | NR |
| Kato et al. ( | Japan | Cross‐sectional | 17 ASD 18 TD | 100 | 12.0 (1.5) | 105.12(13.24) | HFA | DSM‐5, ADOS‐G | WISC‐IV; DN‐CAS |
| Lei et al. ( | UK | Cross‐sectional | 81 ASD 39 TD | 69.14 | M:9.63 (4.02) F:9.30 (4.25) | M:97.34 (21.00) F: 97.20 (21.34) | HFA | DSM‐5, ADI‐R, ADOS; SRS‐2 | WAIS |
| Boets et al. ( | Belgium | Cross‐sectional | 17 ASD 17 TD | 100 | 13.8 (1.3) | 105 (14) | HFA | DSM‐IV; SRS | NR |
| Fitzgerald et al. ( | Ireland | Cross‐sectional | 45 ASD 45 TD | 100 | 16.55 (3.04) | 109.5 (15.9) | HFA | ADI‐R, ADOS‐G | NR |
| Zeestraten et al. ( | UK | Cross‐sectional | 98 ASD 115 TD | 62.24 | M:26.0 (7.0) F:25.4 (6.1) | M:115.3 (12.6) F:113.7 (15.0) | AS | ICD‐10, ADI‐R, ADOS‐Module 4 | WAIS |
| Catani et al. ( | UK | Cross‐sectional | 61 ASD 61 TD | 100 | 26 (6.9) | 111 (13) | HFA, AS | ICD‐10, DSM‐IV, ADI‐R, ADOS; AQ | WAIS |
| Libero et al. ( | USA | Cross‐sectional | 42 ASD 44 TD | 85.71 | 19.9 (1.27) | 112.9 (1.99) | HFA | ADI‐R, ADOS‐G; AQ; RAADS‐R | WAIS |
| Moseley et al. ( | UK | Cross‐sectional | 18 ASD 14 TD | 83.3 | 30.39 (9.99) | 112.72 (22.56) | HFA, AS | DSM‐IV; AQ | NR |
| Samson et al. ( | Switzerland | Cross‐sectional | 18 ASD 18 TD | 88.9 | 13.06 (3.57) | 104 (18.25) | HFA | DSM‐IV, ADI‐R, ADOS; SRS | Stanford Binet‐5 |
| Lu et al. ( | USA | Cross‐sectional | 25 ASD 20 TD | 68 | 11.3 (3.48) | 108.9 (15.28) | HFA | ADOS; | CELF‐4; KBIT‐2 |
| Roine et al. ( | Finland | Cross‐sectional | 14 ASD 19 TD | 100 | 28.6 (5.7) | 125.1 (14.5) | AS | ICD‐10; AQ | WASI‐III |
| Joseph et al. ( | USA | Cross‐sectional | 20 ASD 20 TD | 90 | 5.91 (1.25) | 96 (23) | HFA | ADI‐R, ADOS | CELF‐III; KBIT‐2; DAS; OWLS |
| Roberts et al. ( | USA | Cross‐sectional | 18 ASD 25 TD | 88.9 | 11.47 (3.25) | >75 | HFA | ADOS; SRS | WISC‐IV, CELF‐4 |
| Sharda et al. ( | India | Cross‐sectional | 22 ASD 22 TD | 72.7 | 11.0 (3.4) | 83.14 (17.8) | ASD | DSM‐IV, ADOS‐G | WASI |
| Verly et al. ( | Belgium | Cross‐sectional | 17 ASD 25 TD | 82.3 | 13.95 (1.34) | 88.24 (19.20) | HFA | DSM‐IV; SRS | WISC‐III, CELF‐4, PPVT |
| McGrath et al. ( | Ireland | Cross‐sectional | 25 ASD 25 TD | 100 | 17.28 (2.87) | 106.84 (14.54) | HFA | ADOS‐G, ADI‐R | WISC–IV, WAIS‐III |
| Mills et al. ( | USA | Cross‐sectional | 10 ASD 17 TD | 80 | 9.2 (1.8) | 94.2 (16) | HFA | DSM‐IV, ADI‐R, ADOS | WISC–IV, CELF‐4 |
| Peeva et al. ( | USA | Cross‐sectional | 18 ASD 18 TD | 83.3 | 25.6 (9.2) | 112.4 (9.7) | HFA | DSM‐IV, ADI‐R, ADOS‐Module 4 | American National Adult Reading Test |
| Billeci et al. ( | Italy | Cross‐sectional | 22 ASD 10 TD | NR | 5.54 (2.03) | 70.5 (23.31) | ASD | DSM‐IV, ADOS‐G; CARS | WPPSI, WISC‐R |
| Lai et al. ( | USA | Cross‐sectional | 16 ASD 18 TD | 87.5 | 11.02 (3.72) | <80 | ASD | DSM‐IV, ADI‐R | Clinical observation of words uttered |
| Nagae et al. ( | USA | Cross‐sectional | 18 ASD 25 TD | NR | 11.3 (6.7–17.5) | 108 (10) | HFA | ADOS; SRS | WISC‐IV, CELF‐4 |
| Poustka et al. ( | Germany | Cross‐sectional | 18 ASD 18 TD | 88.9 | 9.7 (2.1) | 111.0 (14.4) | HFA | ICD‐10, ADI‐R, ADOS | Raven's Colored Progressive Matrices Test |
| Verhoeven et al. ( | Belgium | Cross‐sectional | 19 ASD 21 TD | 84.2 | 13.8 (1.6) | 90.5 (18.7) | HFA | DSM‐IV; SRS | WISC‐III, CELF‐4 |
| Ameis et al. ( | Canada | Cross‐sectional | 19 ASD 16 TD | 84.21 | 12.4 (3.1) | 98.5 (20.4) | HFA | DSM‐IV, ADI‐R, ADOS | WISC‐IV |
| Cheon et al. ( | Korea | Cross‐sectional | 17 ASD 17 TD | 100 | 11.0 (2.1) | 112.1 (12.0) | HFA | DSM‐IV, ADI‐R‐K, ADOS‐K; SRS | WISC‐R‐III |
| Jou et al. ( | USA | Cross‐sectional | 10 ASD 10 TD | 100 | 13.06 (3.85) | 91.0 (24.79) | HFA | DSM‐IV, ADI‐R, ADOS | WISC‐III |
| Thomas et al. ( | USA | Cross‐sectional | 12 ASD 18 TD | 100 | 28.5 (9.7) | 106.92 (10.47) | HFA | DSM‐IV, ADI‐R, ADOS‐G | WAIS‐III |
| Fletcher et al. ( | USA | Cross‐sectional | 10 ASD 10 TD | 100 | 14.25 (1.92) | 103.7 (18.55) | HFA | ICD‐10, ADI‐R, ADOS‐G | WISC, CELF‐III |
| Knaus et al. ( | USA | Cross‐sectional | 14 ASD 20 TD | 100 | 16.09 (2.3) | 103.29 (NR) | HFA | DSM‐IV, ADI‐R, ADOS | CELF‐III; KBIT‐2 |
| Kumar et al. ( | USA | Cross‐sectional | 32 ASD 16 TD | 90.6 | 5.0 (2.5–8.9) | >80 | HFA | DSM‐IV; CARS‐2 | WPPSI‐III, WISC‐IV |
| Brito et al. ( | Brazil | Cross‐sectional | 8 ASD 8 TD | 100 | 9.53 (1.83) | NR | ASD | DSM‐IV | NR |
| Pugliese et al. ( | UK | Cross‐sectional | 24 ASD 42 TD | 100 | 23.3 (12.4) | 104.7 (12.05) | AS | ICD‐10, ADI‐R, ADOS | WAIS |
Abbreviations: ADI‐R, autism diagnostic interview‐revised; ADOS, autism diagnostic observation schedule; ADOS‐G, autism diagnostic observation schedule‐generic; AQ, autism‐spectrum quotient; AS, Asperger syndrome; ASD, autism spectrum disorder; CARS, Childhood Autism Rating Scale; CELF, clinical evaluation of language fundamentals; DAS, Differential Ability Scales; DN‐CAS, Das‐Naglieri cognitive assessment system; DSM, diagnostic and statistical manual of mental disorder; F, female; FSIQ, full‐scale IQ; HFA, high‐functioning autism; ICD‐10, international statistical classification of diseases; KBIT, Kaufman brief intelligence tests; M, male; NR, not reported; OWLS, Oral and Written Language Scales; PPVT, Peabody Picture Vocabulary Test; RAADS‐R, Ritvo Autism‐Asperger Diagnostic Scale‐Revised; SD, standard deviation; SRS, Social Responsiveness Scale; TD, typically developing individuals; VIQ, verbal IQ; WASI, Wechsler Abbreviated Scale of Intelligence; WISC, Wechsler Intelligence Scale for Children; WPPSI, Wechsler Preschool and Primary Scale of Intelligence.
Methodological details of included articles
| Study | Image acquisition | Analysis method | ROI tract | DTI metrics | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tesla | TE (ms) | TR (ms) | FOV (mm2) | No. of directions |
| Software | Type of analysis | Measures of head motions | AF | SLF | ILF | IFOF | UF | FA | MD | AD | RD | Vol | Nb | LI | |
| Andica et al. ( | 3 | 100 | 9810 | 256*256 | 32 | 2000 | FSL | Atlas‐based | ○ | × | ○ | ○ | ○ | ○ | ○ | ○ | × | ○ | × | × | × |
| Kato et al. ( | 3 | 74.3 | 12,000 | 260*260 | 25 | 1000 | Explore‐DTI | Deter | ○ | × | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Lei et al. ( | 3 | 85 | 6200 | 240*240 | 30 | NR | FSL | Atlas‐based | ○ | × | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Boets et al. ( | 3 | 65 | 7600 | 240*200 | 60 | 1300 | TRACULA | Prob | ○ | × | ○ | ○ | × | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Fitzgerald et al. ( | 3 | 79 | 20,122 | 248*248 | 61 | 1500 | Explore‐DTI | Deter | ○ | × | ○ | × | × | × | ○ | × | × | × | × | × | ○ |
| Zeestraten et al. ( | 3 | 104.5 | 20R‐R intervals | 307*307 | 32 | 1300 | Explore‐DTI/FSL | Deter | ○ | ○ | × | ○ | ○ | ○ | ○ | × | × | × | × | × | × |
| Catani et al. ( | 3 | 104.5 | 20R‐R intervals | 307*307 | 32 | 1300 | Explore‐DTI | Deter | ○ | ○ | × | ○ | ○ | ○ | ○ | ○ | × | ○ | × | ○ | × |
| Libero et al. ( | 3 | 90 | 7000 | 220*220 | 46 | 1000 | mrDiffusion Package | Deter (AFQ) | ○ | × | ○ | ○ | × | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Moseley et al. ( | 3 | 90 | 7800 | 192*192 | 64 | 1000 | FSL | Prob | ○ | ○ | × | × | × | × | ○ | ○ | × | × | ○ | × | × |
| Samson et al. ( | 3 | NR | NR | NR | 30 | 1200 | AFQ | Deter | ○ | × | × | × | × | ○ | ○ | × | × | × | × | × | × |
| Lu et al. ( | NR | 84 | 9300 | 256*256 | 30 | 700 | TRACULA | Automatic Prob | ○ | ○ | × | ○ | × | × | ○ | ○ | ○ | ○ | × | × | × |
| Roine et al. ( | 3 | 98 | 10,000 | 240*240 | 60 | 1000 | Explore‐DTI | CSD‐based | ○ | × | ○ | ○ | ○ | ○ | ○ | ○ | × | × | × | × | ○ |
| Joseph et al. ( | 3 | 91 | 10,646 | 230*230 | 15 | 1000 | FSL | Prob | ○ | ○ | × | × | × | × | ○ | ○ | ○ | ○ | × | × | ○ |
| Roberts et al. ( | 3 | 70 | 14,000 | 256*256 | 30 | 1000 | DTIStudio | Deter | ○ | ○ | × | × | × | × | ○ | ○ | ○ | ○ | × | × | × |
| Sharda et al. ( | 3 | 45 | 8000 | 240*240 | 16 | 1000 | FSL | Atlas‐based | ○ | ○ | ○ | ○ | × | ○ | ○ | × | × | × | × | × | ○ |
| Verly et al. ( | 3 | 55 | 11,043 | 220*220 | 45 | 800 | Explore‐DTI | Deter | ○ | × | ○ | × | × | × | ○ | × | × | × | × | ○ | × |
| McGrath et al. ( | 3 | 79 | 20,122 | 128*128 | 61 | 1500 | Explore‐DTI | CSD‐based | ○ | ○ | × | × | ○ | × | ○ | × | × | × | × | × | × |
| Mills et al. ( | 1.5 | NR | NR | 240*240 | 51 | 600/800/1000 | DTIStudio | Deter | ○ | ○ | ○ | ○ | ○ | ○ | ○ | × | × | × | × | × | × |
| Billeci et al. ( | 1.5 | 107 | 11,000 | 190*190 | 25 | 1000 | FSL | Deter | ○ | ○ | × | × | × | × | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Lai et al. ( | 1.5 | 81.9 | 8500 | NR | 25 | 1000 | FSL | Prob | ○ | ○ | × | × | × | × | ○ | × | × | × | × | × | × |
| Peeva et al. ( | 3 | 82 | 8400 | NR | 72 | 700 | FSL | Prob | ○ | ○ | × | × | × | × | ○ | × | × | × | ○ | ○ | × |
| Negae et al. ( | 3 | 70 | 14,000 | 256*256 | 30 | 1000 | DTIStudio | Deter | ○ | × | ○ | × | × | × | ○ | ○ | × | × | × | × | × |
| Poustka et al. ( | 1.5 | 78 | 4700 | 192*192 | 6 | 1000 | NeuroQLab | Deter | ○ | × | ○ | × | × | ○ | ○ | × | × | × | × | × | × |
| Verhoeven et al. ( | 3 | 55 | 11,043 | 220*220 | 45 | 800 | Explore‐DTI | Deter | ○ | × | ○ | × | × | × | ○ | × | × | × | × | × | × |
| Ameis et al. ( | 3 | 80 | 4100 | 210*210 | 12 | 1250 | FSL | Atlas‐based | ○ | × | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Cheon et al. ( | 1.5 | 86 | 6500 | 230*230 | 30 | 900 | FSL | Atlas‐based | ○ | × | × | ○ | × | ○ | ○ | ○ | ○ | ○ | × | × | × |
| Jou et al. ( | 1.5 | 92 | 11,200 | 256*256 | 6 | 1000 | BioImage | Deter | ○ | × | ○ | ○ | ○ | × | ○ | × | × | × | ○ | × | × |
| Thomas et al. ( | 3 | 82 | 4900 | 210*210 | 12 | 850 | DTIStudio | Deter | ○ | × | × | ○ | ○ | ○ | ○ | × | × | × | ○ | ○ | ○ |
| Fletcher et al. ( | 3 | 84 | 7000 | 256*256 | 12 | 1000 | ITK‐SNAP | Prob | ○ | ○ | × | × | × | × | ○ | ○ | ○ | ○ | ○ | × | ○ |
| Knaus et al. ( | 3 | 73 | NR | 230*230 | 15 | 1000 | FSL | Prob | ○ | ○ | × | × | × | × | ○ | × | × | × | × | × | × |
| Kumar et al. ( | 3 | 79 | NR | 240*240 | 6 | 1000 | DTIStudio | Deter | ○ | ○ | × | × | ○ | ○ | ○ | × | × | × | ○ | × | × |
| Brito et al. ( | 1.5 | 90 | 3100 | 250*250 | 12 | 1000 | DTI Task Card | Atlas‐based | ○ | × | ○ | ○ | × | × | ○ | ○ | × | × | × | × | × |
| Pugliese et al. ( | 3 | 107 | 15R‐R intervals | 240*240 | NR | 1300 | NR | Deter | ○ | × | × | ○ | ○ | ○ | ○ | ○ | × | × | × | ○ | × |
Abbreviations: ×, no referred in individual studies; ○, referred in individual studies; AD, axial diffusivity; AF, arcuate fasciculus; AFQ, automated fiber quantification; CSD‐based, constrained spherical deconvolution‐based tractography; Deter, deterministic tractography; FA, fractional anisotropy; FOV, field of view; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; L‐, left hemisphere; LI, laterality index; MD, mean diffusivity; Nb, number of streamlines; Prob, probabilistic tractography; R‐, right hemisphere; RD, radial diffusivity; ROI, region of interest; SLF, superior longitudinal fasciculus; TE, echo time; TR, repetition time; UF, uncinate fasciculus; Vol, volume.
FIGURE 2Overall meta‐analysis of FA/MD in each language‐related tract. AF, arcuate fasciculus;FA, fractional anisotropy; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; I‐squared, between‐study heterogeneity for individual meta‐analyses; L, left hemisphere; MD, mean diffusivity; Pub bias(p), p‐value of Egger's test for individual meta‐analyses; p‐value, p‐value of the effect size for individual meta‐analyses; R, right hemisphere; SLF, superior longitudinal fasciculus; smd, effect size for individual meta‐analyses; UF, uncinate fasciculus
FIGURE 3Subgroup analysis of fractional anisotropy in each language‐related tract
FIGURE 4Subgroup analysis of mean diffusivity in each language‐related tract
Summary table of meta‐regression results
| Tract | Dependent variable | Sex ratio | Verbal IQ | SRS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| Dorsal Pathway | AF/SLF | L_FA | 23 | 0.001 | 0.009 | 0.293 | 12 | 0.046 | 0.023 | 0.073 | 6 | −0.002 | 0.016 | 0.897 |
| R_FA | 20 | 0.0005 | 0.009 | 0.962 | 11 | 0.034 | 0.031 | 0.307 | 6 | −0.011 | 0.016 | 0.537 | ||
| L_MD | 10 | 0.013 | 0.02 | 0.532 | 3 | — | — | — | — | — | — | — | ||
| R_MD | 10 | −0.001 | 0.014 | 0.923 | 3 | — | — | — | — | — | — | — | ||
| Ventral Pathway |
| L_FA | 11 | 0.008 | 0.006 | 0.211 | 8 | 0.067 | 0.031 | 0.068 | — | — | — | — |
| R_FA | 11 | 0.002 | 0.005 | 0.76 | 7 | 0.042 | 0.022 | 0.16 | — | — | — | — | ||
|
| L_FA | 10 | 0.008 | 0.009 | 0.388 | 7 | 0.053 | 0.045 | 0.286 | — | — | — | — | |
| R_FA | 10 | 0.004 | 0.008 | 0.604 | 8 | 0.049 | 0.026 | 0.111 | — | — | — | — | ||
|
| L_FA | 10 | 0.011 | 0.008 | 0.22 | 5 | — | — | — | — | — | — | — | |
| R_FA | 8 | 0.001 | 0.007 | 0.191 | 5 | — | — | — | — | — | — | — | ||
Note: k: Number of studies; —: No sufficient studies; Factor significance was set at p < 0.01, and there were no statistically significant results in any meta‐regression.